Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth 2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-YearCompany Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic GrowthGenerated $25.5 Million of Cash from Operations in 2025; as of December 31, 2025 had $75.5 Million of...
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders – Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clini...
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy Company Reports Record Revenue and Profitability for Full-Year 2025 REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately NIS 0.77) per share on the Co...
Scouring the data in this report, we’d point you to the appendix for a quick review. What stands out is that when a broadband customer interacts with a sales rep, presumably they are doing so with a problem or request that an automated or AI-driven IVR cannot address. Almost without fail, sales rep interactions are the Achilles heal of the market right now and likely a core reason, care scores suffer. The operator that can solve this puzzle, and it could be cable, has a window to shift their rel...
Stantec announces renewal of Normal Course Issuer Bid and Automatic Share Purchase Plan EDMONTON, Alberta, March 10, 2026 (GLOBE NEWSWIRE) -- TSX, NYSE: STN Stantec Inc. (“Stantec”), a global leader in sustainable design and engineering, announced today that it has received approval from the Toronto Stock Exchange (the “TSX”) regarding the renewal of its Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB documentation filed with the TSX, Stantec may purchase up to 2,281,339 common shares of Stantec (“Common Shares”), representing approximately 2% of Stantec’s 114,066,995 issued and ...
Net, we would emphasize: 1) the US Government's recognition of the threat quantum computing systems will eventually pose to classical cryptography (as well as current threats from potential bad actors to "harvest now, decrypt later") as well as 2) the apparent need to implement and deploy post-quan
The AI buildout is accelerating in 2026, and we see it is getting difficult to track what is being deployed, by whom, for what usage, with what financing, and on what underlying business model. As GTC approaches, we address all these questions in a series of one-sliders. Today we look into who pays for all these Enterprise Cloud AI bills. Note: For our latest estimates, please see updates to the slides published earlier this week; we are refining our numbers in real time as we progress in this...
The AI buildout is accelerating in 2026, and we see it is getting difficult to track what is being deployed, by whom, for what usage, with what financing, and on what underlying business model. As GTC approaches, we address all these questions in a series of one-sliders. Today we look into how frontier labs can absorb rising compute costs in 2027 and beyond. Note: For our latest estimates, please see updates to the slides published earlier this week; we are refining our numbers in real time as...
A director at Kinross Gold Corp maiden bought 1,073 shares at 46.600CAD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Two Directors at Barrick Mining Corp bought/sold after exercising options/maiden bought 29,367 shares at 68.400CAD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the ...
What’s new: Bilibili’s reported 4Q25 results that were above consensus and our expectations. Gaming revs could continue to be adversely impacted by tougher comps in San Mou. Ad growth could remain resilient in CY26 partly driven by further improvement in conversion and continued increase in user traffic. Margins could be partly impacted by investments in AI. We maintain our PT at USD29. Analysts: Jin Yoon
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.